

12B1 tumor sup
B16 tumor sup
4T1 tumor sup
12.48%
14.03%
12.59%
No emTh-1 sup
0.72%
0.71%
0.63%
emTh-1 sup
FoxP3
CD4

FIG. 1A



No emTh-1 sup
emTh-1 sup
% FoxP3+ cells
18
16
14
12
10
8
6
4
2
0
*
*
*
12B1 sup
4T1 sup
B16 sup

FIG. 1B




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D



% of FoxP3 positive cells
30
25
20
15
10
5
0
no TGFβ
TGFβ
TGFβ + emTh-1 sup 12%
TGFβ + emTh-1 sup 25%
TGFβ + emTh-1 sup 50%
TGFβ + emTh-1 sup 75%
TGFβ + emTh-1 sup 100%

FIG. 2E



0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
O.D. 450nm
CD25-
CD25-
+GFP+iTreg
CD25-
+[+GFP+iTreg]$_{1}$emTh-1 sup

FIG. 2F



1.4
12
1.0
0.8
0.6
0.4
0.2
0
O.D. 450nm
CD25-
CD25-
+untreated ITreg
CD25-
+ITregJemTh-1 sup

FIG. 2G




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D



CD25-
27.68%
47.34%
12.98%
CD25-
+ untreated Treg
68.58%
9.29%
0.85%
CD25-
+ [Treg]emTh-1 sup
46.81%
33.94%
3.06%

FIG. 4E



Untreated CD25-
27.68%
47.34%
12.98%
Untreated CD25-
+ Treg
61.04%
1.3%
1.34%
[CD25-]emTh-1 sup
+ Treg
31.61%
45.99%
6.71%

FIG. 4F




FIG. 5A




FIG. 5B




FIG. 5C



100
50
0
Percent Survival
0
10
20
30
40
Days
Control
emTh1 + B16 CRCL

FIG. 5D




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D

FIG. 7A

FIG. 7B

FIG. 7C